Results 181 to 190 of about 534,212 (263)

Longitudinal Modulation of the Gut Microbiome and Growth Performance by Phytochemicals as Antibiotic Alternatives in Swine Production

open access: yesAnimal Research and One Health, EarlyView.
We conducted a longitudinal trial across nursery, growing, and finishing phases, showing that phytochemical supplementation as a potential antibiotic alternative reduced potential pathogens and promoted beneficial Lactobacillus amylovorus in the nursery phase, and enriched amino acid and carbohydrate metabolism pathways (prediction) during finishing ...
Ziyu Liu   +11 more
wiley   +1 more source

Structural Alerts for Aneuploidy Prediction: Are We There Yet? [PDF]

open access: yesToxics
Ricci EM   +4 more
europepmc   +1 more source

Disulfide Bond–Modified Proteomics Reveals the Effects of Riboflavin on Protein Folding Dynamics

open access: yesAnimal Research and One Health, EarlyView.
Riboflavin deficiency impairs oxidative protein folding, causing ER misfolded protein accumulation, CHOP activation, and apoptosis, revealing a role of riboflavin in proteostasis. ABSTRACT Riboflavin is a crucial micronutrient essential for maintaining cellular homeostasis, acting as an important precursor for flavoproteins that utilize flavin ...
Bo Zhang, Shuisheng Hou, Jing Tang
wiley   +1 more source

CT-based automatic segmentation of key CSF regions for detecting disproportionately enlarged subarachnoid space hydrocephalus. [PDF]

open access: yesFluids Barriers CNS
Yamada S   +11 more
europepmc   +1 more source

A Multifaceted Interplay Among Hemophagocytosis, Interleukin‐18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller   +16 more
wiley   +1 more source

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi   +30 more
wiley   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

open access: yesArthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy